Together the two companies will offer a complete set of packages for phase I studies, including development and manufacture of clinical trial material. The scope will cover planning, performing and evaluation of the clinical trial.
Maria Lundberg, general manager, Recipharm Pharmaceutical Development, said, “CTC has experience in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset). Together we will be able to offer customers faster and more cost-efficient phase I studies. We can from now on take full responsibility for coordination of the work, which might be valuable to small, virtual companies.”
Bengt Dahlström, CEO of CTC Clinical Trial, said, “I am very pleased that CTC and Recipharm now can offer a joint service, which will benefit from the companies longstanding expertise in contract development and manufacturing and early clinical research. This systematic integrated approach will help our clients to shorten project timelines and at the same time obtain more information on the desirable properties of the drug formulation. Adaptive design is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol.”